During the past decade, Oita University Hospital conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 2 clinical trials were completed, i.e. on average, 16.7% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 2 clinical trials were completed. i.e. 22.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Oita University Hospital" #1 sponsor was "Eli Lilly and Company" with 4 trials, followed by "Bayer" with 2 trials sponsored, "Chugai Pharmaceutical" with 2 trials sponsored, "Janssen Pharmaceutical K.K." with 1 trials sponsored and "Japan Foundation for Neuroscience and Mental Health" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Oita University Hospital" #1 collaborator was "Japan Lung Cancer Society" with 2 trials as a collaborator, "Korean Gynecologic Oncology Group" with 1 trials as a collaborator, "Medtronic" with 1 trials as a collaborator, "Medtronic Japan Co., Ltd." with 1 trials as a collaborator and "National Center of Neurology and Psychiatry, Japan" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Oita University Hospital" are "Alzheimer Disease" (4 trials), "Cancer" (1 trials), "Chronic Pain" (1 trials), "Epithelial Ovarian Cancer" (1 trials) and "Extensive Disease Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "Oita University Hospital" in a lesser frequency.

Most popular intervention types in "Oita University Hospital" are "Drug" (11 trials), "Behavioral" (1 trials), "Biological" (1 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Donanemab" (2 trials), "Abiraterone" (1 trials), "Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)" (1 trials) and "Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Oita University Hospital" are 12 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Oita University Hospital". undefined are not yet recruiting, 5 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Oita University Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Oita University Hospital, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".